Biosynex sells its molecular biology business

Biosynex, a company listed on Euronext Growth, has completed the sale of its molecular biology business. This transaction follows the fulfillment of conditions precedent and approval by the bankruptcy judge. The sale agreement was signed on June 10, 2026, following the agreement of the relevant creditors.

This operation is part of Biosynex's strategy to refocus on Rapid Diagnostic Tests (RDTs) and Therapeutic Drug Monitoring (TDM). Concurrently, the liquidation of its subsidiary Avalun led to the acceptance of an offer for its financial assets.

In addition, Jérôme Silvestre resigned from his position as a censor on the Board of Directors for personal reasons effective May 30, 2026. Biosynex is thus continuing its growth strategy.